매독 시장 : 세계 및 지역별 분석 - 치료법별, 투여 경로별, 지역별 - 분석과 예측(2026-2036년)

This report can be delivered within 1 working day.

Introduction of the Syphilis Market

The global syphilis market, initially valued at $718.0 million in 2024, is projected to grow substantially, reaching $1,220.8 million by 2036, reflecting a remarkable compound annual growth rate (CAGR) of 4.60% from 2026 to 2036.

The global syphilis market is experiencing significant growth, driven by the rising incidence of sexually transmitted infections, increasing awareness regarding early diagnosis and treatment, and the expanding availability of screening programs across both developed and developing regions. Growing public health initiatives, improved access to diagnostic testing, and stronger efforts by healthcare organizations to control the spread of syphilis are contributing to market expansion.

In addition, advancements in diagnostic technologies, including rapid testing methods and more accurate laboratory-based assays, are improving detection rates and supporting timely clinical intervention. The market is also benefiting from greater emphasis on maternal and prenatal screening to prevent congenital syphilis, alongside increasing investments in infectious disease management and sexual health programs. As demand for effective diagnosis, treatment, and prevention strategies continues to rise, the global syphilis market is expected to maintain steady growth over the forecast period.

Market Introduction

The global syphilis market has experienced steady growth and is projected to continue expanding, driven by increasing awareness, advancements in diagnostic methods, and growing public health efforts to control the spread of sexually transmitted infections (STIs). The market growth is primarily fuelled by rising syphilis incidence rates, particularly in high-risk populations, and an increasing focus on early diagnosis and treatment to reduce transmission and prevent complications, including congenital syphilis. Enhanced access to diagnostic tests, including rapid point-of-care tests and improved laboratory diagnostics, is playing a key role in driving market expansion. Additionally, the rise of government initiatives and healthcare programs aimed at improving sexual health awareness, alongside the growing demand for more effective treatment options, further supports the market's growth trajectory.

Industrial Impact

The global syphilis market has witnessed significant growth, driven by the increasing demand for improved diagnostics, treatments, and preventive measures. This growth is having a substantial impact across various industries, including healthcare, pharmaceuticals, and public health. In the healthcare industry, the rise in syphilis cases has led to greater emphasis on early detection and effective management, encouraging the adoption of advanced diagnostic tools like rapid testing kits and improved laboratory assays.

In the pharmaceutical sector, there has been a growing focus on developing new treatments and therapeutic options for syphilis, as well as medications to address co-infections often associated with the disease. This has spurred innovation and investment in research and development, contributing to the growth of the pharmaceutical industry.

The public health sector is also significantly impacted, with governments and non-governmental organizations ramping up efforts to combat syphilis through awareness campaigns, vaccination programs, and prenatal screenings to prevent congenital syphilis. These efforts are increasing demand for more accessible testing and treatment options, thus shaping the market dynamics and driving further industry advancements.

The synergy between these sectors is fostering a more robust and integrated response to syphilis, ultimately enhancing global health outcomes while driving continued growth in the market.

Market Segmentation:

Segmentation 1: By Route of Administration

• Injectables
• Oral Medications

Injectables Segment to Dominate the Syphilis Market (by Route of Administration)

The injectables segment is expected to dominate the syphilis market by route of administration, driven by the proven efficacy of injectable antibiotics, particularly penicillin, in treating syphilis infections. Penicillin remains the standard treatment for syphilis, especially in its later stages, such as tertiary syphilis or congenital syphilis. The injectable form of penicillin is preferred due to its high bioavailability and ability to provide a rapid and reliable therapeutic effect.

Injectables are particularly favoured in clinical settings due to their ability to ensure consistent and controlled dosing, which is essential for effectively treating syphilis and preventing complications. The intramuscular (IM) administration of penicillin, commonly in the form of Benzathine penicillin G, is the recommended treatment for syphilis across various stages of infection. This method of administration ensures that the antibiotic remains active in the body for a prolonged period, helping to eliminate the syphilis-causing bacterium, Treponema pallidum.

As the standard treatment remains an injectable, and due to the growing number of syphilis cases globally, the injectables segment is anticipated to continue its dominance in the market, supported by the established clinical guidelines and the proven effectiveness of injectable antibiotics.

Segmentation 2: By Treatment Type

• Penicillin-based Treatment
• Other Antibiotics

Penicillin-based Treatment to Dominate the Syphilis Market (by Treatment Type)

Penicillin-based treatment is expected to dominate the syphilis market by treatment type, as penicillin remains the gold standard for syphilis therapy due to its proven effectiveness in curing the infection. Penicillin, particularly Benzathine penicillin G, is widely used to treat syphilis at all stages, from primary and secondary to latent and tertiary syphilis. It is the preferred treatment because it is highly effective against the causative bacterium, Treponema pallidum, and has been the cornerstone of syphilis management for decades.

Penicillin's dominance is supported by its long history of clinical success and established guidelines from global health organizations, including the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), which recommend it as the first-line treatment for syphilis. The injectable form of penicillin ensures that the drug remains in the system for a prolonged period, offering a reliable, single-dose solution for treating syphilis.

Due to its widespread availability, affordability, and strong clinical evidence, penicillin-based treatments will continue to be the most prescribed and preferred option for syphilis treatment, maintaining their dominant position in the market for the foreseeable future.

Segmentation 3: By Region

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest-of-Europe
• Asia and Oceania
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest-of-Asia and Oceania
• Rest-of-the-World
  • Latin America and Caribbean
  • North Africa and Middle East

Asia and Oceania to Dominate the Syphilis Market (by Region)

Asia and Oceania are expected to dominate the syphilis market due to the rising incidence of sexually transmitted infections (STIs), increasing awareness, and improving healthcare infrastructure in the region. With high population densities and expanding access to healthcare, both regions are experiencing significant public health efforts to combat syphilis through early diagnosis, treatment, and prevention programs.

In Asia, countries such as China, India, and Japan are witnessing an uptick in syphilis cases, driven by factors such as urbanization, changing sexual behaviors, and a growing focus on sexual health. These countries are also increasing their efforts in STI prevention through government programs, screening initiatives, and awareness campaigns, which are contributing to market growth. The expansion of healthcare services, especially in rural areas, is further driving demand for diagnostic tests and treatments.

In Oceania, particularly in Australia and New Zealand, public health authorities are emphasizing the importance of syphilis screening, particularly for pregnant women, to prevent congenital syphilis. Additionally, the implementation of robust healthcare systems, along with a growing focus on sexual health, is promoting syphilis testing and treatment availability.

As awareness and healthcare access continue to improve in these regions, Asia and Oceania are set to maintain a dominant position in the global syphilis market, driven by increased demand for effective diagnosis and treatment options.

Recent Developments in the Syphilis Market

• As of February 2026, Aurobindo Pharma Limited expects Penicillin-G (Pen-G) production to reach ~10,000 metric tonnes within 12 months as it scales output from its integrated Andhra Pradesh facility.
• In January 2026, India imposed a one-year minimum import price (MIP) on penicillin and key derivatives (Pen-G, 6-APA, amoxicillin trihydrate) to curb low-cost imports, especially from China, and protect domestic manufacturers such as Aurobindo Pharma Limited.
• In March 2025, Sandoz Group AG opened a new €50 million antibiotic production facility in Kundl, Austria, boosting output by ~20% (to 240 million packages/year) and enabling production of one billion additional penicillin tablets to meet rising global demand.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Rising Incidence of Syphilis: The global resurgence of syphilis reflects systemic gaps in prevention, early detection, and sustained public health investment, even in high-income settings. Disproportionate impacts among MSM, people living with human immunodeficiency virus (HIV), and pregnant women indicate persistent structural and behavioural vulnerabilities, while rising congenital cases signal critical failures in maternal screening and treatment programs. The convergence of reduced condom use, digital sexual networking, stigma, and uneven healthcare access suggests that current control strategies are insufficiently adaptive. Without integrated, population-specific interventions and strengthened surveillance, projections of sustained high incidence through 2035 are likely to materialize.

Market Challenges

Recurrent Shortage of the Primary Treatment, Benzathine Penicillin G: The recurrent shortage of benzathine penicillin G (BPG), the gold-standard first-line therapy for syphilis, is significantly constraining market growth. Persistent supply disruptions, manufacturing concentration, and low-margin economics limit consistent drug availability, particularly for high-risk groups such as pregnant women. This instability forces reliance on alternative regimens with clinical limitations, reducing adherence to treatment guidelines and affecting overall treatment volumes. Additionally, procurement uncertainty and backorders weaken revenue predictability for manufacturers and public health programs. Without supply chain diversification and production incentives, BPG shortages will continue to act as a structural restraint on the syphilis market.

Market Opportunities

Expansion of Advanced and Accessible Syphilis Diagnostic Testing: The syphilis market is experiencing robust growth driven by innovations in rapid, point-of-care, at-home, and automated testing solutions. FDA-cleared POC and OTC tests, such as the Syphilis Health Check and First to Know Syphilis Test, are expanding access, reducing stigma, and enabling same-day treatment initiation. Dual HIV-syphilis assays and automated treponemal immunoassays are streamlining workflows in high-volume and high-risk settings, improving efficiency and diagnostic accuracy. Market expansion is further supported by public health initiatives, repeat testing protocols, and integration into broader STI screening programs. Analysts view these trends as creating a sustainable growth trajectory, with both decentralized and lab-based testing driving long-term adoption and revenue opportunities.

How can this report add value to an organization?

Product/Innovation Strategy: The global syphilis market has been divided into several key segments, including route of administration, treatment type, and regional markets. By understanding which segments hold the largest share and which ones show potential for growth, this report offers invaluable insights for organizations looking to innovate and expand their product offerings.

Growth/Marketing Strategy: Strategic partnerships, collaborations, and business expansions are anticipated to be central to the growth of the syphilis market.

Competitive Strategy: The syphilis market is highly competitive, with numerous well-established players offering a range of diagnostic solutions and penicillin-based treatments. Pharmaceutical companies focus on providing effective therapies, while diagnostic firms are innovating with faster, more accurate testing methods. Public health organizations also contribute through awareness campaigns and screening programs. As demand for better diagnosis and treatment increases, market players are focusing on enhancing their offerings and expanding their reach to stay competitive.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• Years from 2024 to 2036 have been considered for the global market size estimation, 2024 has been considered as the base year, and 2026 to 2036 as the forecast period.
• The scope of the report is based on insights from industry experts across healthcare, pharmaceuticals, diagnostics, public health, and regulatory bodies. It offers a detailed analysis of the syphilis market, covering trends, growth drivers, competition, and emerging opportunities, while examining factors like advancements in diagnostics and treatment options.
• The market for syphilis is anticipated to grow substantially in the future, with projections based on historical analysis of available solutions.
• Revenues from companies have been sourced from their annual reports for FY2024. For private companies, revenue estimates are derived from primary research inputs, funding history, market collaborations, and operational performance.
• The market has been mapped based on the existing syphilis products and services. Key companies with significant offerings in this field have been identified and profiled in this report.

Primary Research

The primary sources involve industry experts in syphilis, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

• validation and triangulation of all the numbers and graphs
• validation of report segmentations and key qualitative findings
• understanding the competitive landscape and business model
• current and proposed production values of a product by market players
• validation of the numbers of different segments of the market in focus
• percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
• Annual reports, SEC filings, and investors' presentations of the leading market players
• Company websites and a detailed study of their product portfolio
• Gold standard magazines, journals, white papers, press releases, and news articles
• Paid databases

The key data points taken from the secondary sources include:

• segmentations and percentage shares
• data for market value
• key industry trends of the top players in the market
• qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• AdvaCare Pharma
• Centurion Healthcare
• Cipla
• Eurofarma
• Fresenius Kabi AG
• Jolly Healthcare
• Laboratoires Delbert
• Pfizer Inc.
• Sandoz Group AG
• Teva Pharmaceuticals

Table of Contents

Executive Summary

Scope and Definition

1 Global Syphilis Market: Industry Outlook

• 1.1 Market Overview
  • 1.1.1 Market Overview
• 1.2 Epidemiological Analysis
• 1.3 Market Trends
  • 1.3.1 Impact Analysis
    • 1.3.1.1 Integrated Antenatal Infection Panels (HIV-HBV-Syphilis) Becoming a Standard Procurement and Scale-Up Model
    • 1.3.1.2 Self-Testing and Decentralized Testing Expanding the Addressable Treatment Population
• 1.4 Regulatory Landscape
  • 1.4.1 Regulatory Framework in the U.S.
  • 1.4.2 Regulatory Framework in Europe
  • 1.4.3 Regulatory Framework in Asia and Oceania
    • 1.4.3.1 Regulatory Framework in China
    • 1.4.3.2 Regulatory Framework in Japan
    • 1.4.3.3 Regulatory Framework in Australia
• 1.5 Pipeline Analysis
• 1.6 Market Dynamics
  • 1.6.1 Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
  • 1.6.2 Market Drivers
    • 1.6.2.1 Rising Incidence of Syphilis
    • 1.6.2.2 Increased Screening Initiatives
  • 1.6.3 Market Challenges
    • 1.6.3.1 Recurrent Shortage of the Primary Treatment, Benzathine Penicillin G
    • 1.6.3.2 Limited Availability of Alternative Therapies for Syphilis
  • 1.6.4 Market Opportunities
    • 1.6.4.1 Expansion of Advanced and Accessible Syphilis Diagnostic Testing

2 Global Syphilis Market (by Treatment Type), $Million, 2024-2036

• 2.1 Penicillin-based Treatment
  • 2.1.1 Overview
  • 2.1.2 Market Sizing and Forecast
• 2.2 Other Antibiotics
  • 2.2.1 Overview
  • 2.2.2 Market Sizing and Forecast

3 Global Syphilis Market (by Route of Administration), $Million, 2024-2036

• 3.1 Injectables
  • 3.1.1 Overview
  • 3.1.2 Market Sizing and Forecast
• 3.2 Oral Medications
  • 3.2.1 Overview
  • 3.2.2 Market Sizing and Forecast

4 Global Syphilis Market (by Region), $Million, 2024-2036

• 4.1 Regional Summary
• 4.2 North America
  • 4.2.1 Regional Overview
  • 4.2.2 Driving Factors for Market Growth
  • 4.2.3 Factors Challenging the Market
  • 4.2.4 Analyst View
  • 4.2.5 Market Sizing and Forecast
    • 4.2.5.1 North America Syphilis Market, by Country
      • 4.2.5.1.1 U.S.
      • 4.2.5.1.2 Canada
• 4.3 Europe
  • 4.3.1 Regional Overview
  • 4.3.2 Driving Factors for Market Growth
  • 4.3.3 Factors Challenging the Market
  • 4.3.4 Analyst View
  • 4.3.5 Market Sizing and Forecast
    • 4.3.5.1 Europe Syphilis Market, by Country
      • 4.3.5.1.1 U.K.
      • 4.3.5.1.2 Germany
      • 4.3.5.1.3 France
      • 4.3.5.1.4 Italy
      • 4.3.5.1.5 Spain
      • 4.3.5.1.6 Rest-of-Europe
• 4.4 Asia and Oceania
  • 4.4.1 Regional Overview
  • 4.4.2 Driving Factors for Market Growth
  • 4.4.3 Factors Challenging the Market
  • 4.4.4 Analyst View
  • 4.4.5 Market Sizing and Forecast
    • 4.4.5.1 Asia and Oceania Syphilis Market, by Country
      • 4.4.5.1.1 China
      • 4.4.5.1.2 Japan
      • 4.4.5.1.3 India
      • 4.4.5.1.4 South Korea
      • 4.4.5.1.5 Australia
      • 4.4.5.1.6 Rest-of-Asia and Oceania
• 4.5 Rest-of-the-World
  • 4.5.1 Regional Overview
  • 4.5.2 Driving Factors for Market Growth
  • 4.5.3 Factors Challenging the Market
  • 4.5.4 Analyst View
  • 4.5.5 Market Sizing and Forecast
    • 4.5.5.1 Rest-of-the-World Syphilis Market, by Country
      • 4.5.5.1.1 Latin America and Caribbean
      • 4.5.5.1.2 North Africa and Middle East

5 Competitive Benchmarking and Company Profiles

• 5.1 Key Strategies and Developments, January 2021-February 2026
• 5.2 Key Developments Analysis (by Company)
• 5.3 Company Profiles
  • 5.3.1 AdvaCare Pharma
    • 5.3.1.1 Overview
    • 5.3.1.2 Top Products/Product Portfolio
    • 5.3.1.3 Top Competitors
    • 5.3.1.4 Target Customers
    • 5.3.1.5 Key Personnel
    • 5.3.1.6 Analyst View
  • 5.3.2 Centurion Healthcare
    • 5.3.2.1 Overview
    • 5.3.2.2 Top Products/Product Portfolio
    • 5.3.2.3 Top Competitors
    • 5.3.2.4 Target Customers
    • 5.3.2.5 Key Personnel
    • 5.3.2.6 Analyst View
  • 5.3.3 Cipla
    • 5.3.3.1 Overview
    • 5.3.3.2 Top Products/Product Portfolio
    • 5.3.3.3 Top Competitors
    • 5.3.3.4 Target Customers
    • 5.3.3.5 Key Personnel
    • 5.3.3.6 Analyst View
  • 5.3.4 Eurofarma
    • 5.3.4.1 Overview
    • 5.3.4.2 Top Products/Product Portfolio
    • 5.3.4.3 Top Competitors
    • 5.3.4.4 Target Customers
    • 5.3.4.5 Key Personnel
    • 5.3.4.6 Analyst View
  • 5.3.5 Fresenius Kabi AG
    • 5.3.5.1 Overview
    • 5.3.5.2 Top Products/Product Portfolio
    • 5.3.5.3 Top Competitors
    • 5.3.5.4 Target Customers
    • 5.3.5.5 Key Personnel
    • 5.3.5.6 Analyst View
  • 5.3.6 Jolly Healthcare
    • 5.3.6.1 Overview
    • 5.3.6.2 Top Products/Product Portfolio
    • 5.3.6.3 Top Competitors
    • 5.3.6.4 Target Customers
    • 5.3.6.5 Key Personnel
    • 5.3.6.6 Analyst View
  • 5.3.7 Laboratoires Delbert
    • 5.3.7.1 Overview
    • 5.3.7.2 Top Products/Product Portfolio
    • 5.3.7.3 Top Competitors
    • 5.3.7.4 Target Customers
    • 5.3.7.5 Key Personnel
    • 5.3.7.6 Analyst View
  • 5.3.8 Pfizer Inc.
    • 5.3.8.1 Overview
    • 5.3.8.2 Top Products/Product Portfolio
    • 5.3.8.3 Top Competitors
    • 5.3.8.4 Target Customers
    • 5.3.8.5 Key Personnel
    • 5.3.8.6 Analyst View
  • 5.3.9 Sandoz Group AG
    • 5.3.9.1 Overview
    • 5.3.9.2 Top Products/Product Portfolio
    • 5.3.9.3 Top Competitors
    • 5.3.9.4 Target Customers
    • 5.3.9.5 Key Personnel
    • 5.3.9.6 Analyst View
  • 5.3.10 Teva Pharmaceuticals
    • 5.3.10.1 Overview
    • 5.3.10.2 Top Products/Product Portfolio
    • 5.3.10.3 Top Competitors
    • 5.3.10.4 Target Customers
    • 5.3.10.5 Key Personnel
    • 5.3.10.6 Analyst View

6 Research Methodology

• 6.1 Data Sources
  • 6.1.1 Primary Data Sources
  • 6.1.2 Secondary Data Sources
  • 6.1.3 Data Triangulation
• 6.2 Market Estimation and Forecast